All News

Throughout the year, CURE® contributors shared personal stories and reflections highlighting the multifaceted nature of cancer care.

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received at least two prior lines of therapy.

Former U.S. President Jimmy Carter called attention to the immunotherapy drug Keytruda, which was used to successfully treat his cancer.

Jade Distajo has made a profound impact on thousands of patients with her unwavering commitment to exceptional care, compassionate bedside manner and tireless support.

From the benefits of early adoption to the effectiveness of telehealth, here is what we reported about palliative care throughout the year.

Even after a personal connection to cancer, oncology nurse Megan has embraced the cancer space as her passion.

Treatment with five-fraction SBRT for prostate cancer may be more convenient than receiving traditional radiation therapy techniques, an expert said.

Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.

We, survivors, often express our gratitude for life, love, support and research, but what about the patients who do not experience positive outcomes from treatment?

This marks the second FDA approval of Tevimbra this year.

An MPN advocate used his personal experiences to inform his dedication to patient-centered research and support programs for patients.

A patient advocate discusses the difficulties of finding and participating in clinical trials for MPNs, and the impact on research and treatment development.

An expert spoke with CURE® about the importance of information that can be gained from genetic testing for patients with breast cancer.

Nearly 12 years after being diagnosed with ovarian cancer, Julie Brokaw believes life is a miracle.

CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer, in addition to treatment strategies.

The treatment combination was found to reduce the risk of follicular lymphoma progression or death by 57%, a study has shown.

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.

With breakthroughs from melanoma to pancreatic cancer, this has been a year of great promise in the field of cancer vaccines.

A health care professional talks about the importance of a supportive care team, especially since every patient with MPNs presents differently.

After sharing his cancer story online, Jace Yawnick is in a state of technical remission after receiving a diagnosis of non-Hodgkin lymphoma at age 25.

This Christmas, my wish for all of you is that you read this and feel seen, that someone out there knows how very hard this is for you.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated, according to data from a retrospective analysis.

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who progressed on/after chemotherapy.

Utilizing tools such as spreadsheet trackers can make a big difference when organizing cancer-related medical bills and noting out-of-pocket maximums.

Watching "Scrooge" every Christmas made me reflect on my own journey, where my past struggles with illness taught me valuable lessons about forgiveness, love and joy.

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses.

An oncology nurse demonstrated care not only to her patients with cancer but also to her own staff.

Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite instability-high rectal cancer.